Requirement of only one sample preparation.
Simplicity of analysis and assessment.
Suitable pharmacokinetic parameter for vancomycin TDM in patients with
non-severe MRSA and non-MRSA infections [9].
|
Possible errors in exact sampling times [14].
Enhanced risk of vancomycin-associated nephrotoxicity and AKI due to
vancomycin over-dose therapy with a target concentration of 15-20
µg/ml [19].
Higher risk of failure in therapy [22].
Lack of clinical efficacy for the target trough concentration of 15-20
µg/ml [12, 22].
No significant correlation with the AUC-based monitoring approach
[14, 24].
Not recommended in patients with severe MRSA infections [9].
|